GLP1R and myelodysplastic syndrome: Focusing on four common hematologic malignancies (acute myeloid leukemia, multiple myeloma, chronic myeloid leukemia, and myelodysplastic syndrome), we report that GLP-1 receptor agonist use was associated with a reduced risk of multiple myeloma, whereas neither drug class was associated with significantly altered risk for hematologic malignancy in other comparisons.